PharmaView   JUNE.2007

Pharmaceutical Marketers are facing increasing pressures: increasing competition; squeezed margins; shrinking budgets; more to do and less time to do it. It’s becoming difficult to work any harder, and of course it's always better to work smarter. Therefore we bring you the PharmaView.

PharmaView is a biweekly educational and informative newsletter for improving readers’ marketing knowledge and reporting the latest news in the pharma industry. It also provides great opportunities to exchange ideas, network and be recognized among your peers in the industry.

Through PharmaView, you can:

Learn peer’s experience in pharma marketing

Stay in touch with what’s happening in pharmaceutical marketing today

Be on the pioneering edge of pharmaceutical marketing

Have networking / idea exchange opportunities

About Us 

Integrating local knowledge with international perspective, Consultech Co. Ltd. offers its clients and prospects one-lstop solutions with sales and marketing consultancy, advertising and promotion strategies.

Creative Design: Case Study of Ginsana Visuals

Glaxo defends Avandia with full-page newspaper ads

GlaxoSmithKline Plc fired another salvo in defense of diabetes treatment Avandia on Tuesday by taking out full-page advertisements in at least a dozen major U.S. newspapers in an attempt to reassure patients of the safety of the widely used medicine.   

Jun 05, 2007

Copaxone Pre-lFilled Syringe Can Now Be Stored for up to One Month at Room Temperatu

Teva Pharmaceutical Industries, Ltd. and sanofi-aventis today announced that the application for up to one month room temperature storage of COPAXONE(R) (glatiramer acetate injection) pre-lfilled syringe has been approved by the U.S. Food and Drug Administration (FDA) and in Europe under the Mutual Recognition Procedure (MRP).

Jun 07, 2007

FDA Approves Norditropin for Treatment of Short Stature Associated with a Rare Genetic Disorder

Novo Nordisk today announced that Norditropin(R) (somatropin[rDNA origin] injection)received U.S. Food and Drug Administration (FDA) approval for the treatment of short stature in children with Noonan syndrome. Noonan syndrome is defined as an autosomal dominant genetic syndrome commonly characterized by short stature, congenital heart defects, and unique facial features.

Jun 01, 2007

FDA Approves Torisel, a Targeted First-in-Class mTOR Inhibitor for the Treatment of Advanced Kidney Cancer

Wyeth Pharmaceuticals, a division of Wyeth , announced today that the U.S. Food and Drug Administration (FDA) has approved TORISEL(TM) (temsirolimus) for patients with advanced renal cell carcinoma (RCC).

May 30, 2007  

Ask the Expert: Leveraging medical education to improve sales force effectiveness

The buzz about the industry lately: chronic complaints about declining sales force effectiveness. Most everyone agrees that there has to be a better way to reach physicians, but the specified actions to be taken are less clear. For many, the choice remains the same – promotional dinner and lunch programs – the more the better the share of voice. Yet cost pressures challenge this model.

Using new technologies for marketing to consumers

Using new technologies like the Internet for marketing purposes is a challenge for the pharmaceutical industry. It is estimated that the percent of the pharmaceutical marketing budget spent in the ‘e’ space has remained at or below three to five percent since the dawn of the commercial Internet. According to data from Advertising Age, which looks at both measured and unmeasured ad spending, the top 13 pharmaceutical company media spenders in 2005 allocated only 1.2 percent of their budgets on measured Internet advertising.  

What's Hot and What's Not in Oncology

Biotechs have long dominated the stage at the American Society of Clinical Oncology (ASCO), unveiling their latest innovations like magicians pulling rabbits out of hats. But last week's annual ASCO bash in Chicago showed that Big Pharma wants in on the $34 billion-a-year market--and already has a few tricks up its sleeve to show for it.  

Jun 13, 2007

Study backs faster use of Bristol arthritis drug

Rheumatoid arthritis patients who do not respond to anti-TNF therapy can safely switch straight away to Bristol-Myers Squibb Co.'s alternative drug Orencia, researchers said on Wednesday.

Jun 13, 2007

New Drug Application Submitted for Investigational Antibiotic Doripenem

Johnson & Johnson Pharmaceutical Research & Development, L.L.C., (J&JPRD) announced that it has submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for doripenem, an investigational carbapenem antibiotic for the treatment of nosocomial pneumonia, a pneumonia that is acquired in a hospital or other healthcare setting.

Jun 06, 2007

Please feel free to offer your opinions and advices about PharmaView in order to better our services. Should you have any comments, or if you want to unsubscribe  from PharmaView, please send us an email: pharmaview@Consultech.com.cn  . Thank you!